China leading manufacturers and suppliers of Crpc Intermediate No 654-70-6,Crpc Drug Intermediate Cas 403-24-7, Pharma Intermedaite Cas 915087-25-1,and we are specialized in Pharma Intermedaite Cas 654-70-6,Apalutamide Intermediates, etc,which is used for prostate cancer.If you want to buy Pharma Intermedaite Cas 654-70-6,Apalutamide Intermediates,please contact us.
Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and reduced central nervous system permeation. Apalutamide binds weakly to the GABAA receptor similarly to enzalutamide, but due to its relatively lower central concentrations, may have a lower risk of seizures in comparison.
Crpc Intermediate Cas 654-70-6,Crpc Drug Intermediate Cas 403-24-7,Pharma Intermedaite Cas 915087-25-1,Apalutamide Intermediates,prostate cancer  Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com
May 26th, 2014: As the world leader in the automotive interiors industry, the new plant of Germany's Parker Automotive Leather Products (Dalian) Co., Ltd. laid the foundation in Jinzhou New District, Dalian, Liaoning, and the state-level auto parts manufacturing in Jinzhou New District The base further developed and speeded up, and the advantages of the automobile industry cluster became more prominent.
As a state-level “auto parts manufacturing baseâ€, Jinzhou New District has taken full advantage of its industrial base and investment environment to continuously attract international high-end automobile parts and components enterprises. Recently, the world's leading manufacturer of automotive parts manufacturing - the United States Ai Maite brake system Dalian project officially put into operation, the United States Borgwarner automatic transmission and other expansion projects will start construction. These projects will effectively promote the construction of the entire vehicle and parts industry cluster in Jinzhou New District.
Jinzhou New District has already laid out more than 120 complete vehicle and accessory industrial belts led by Brilliance Special Vehicles, FAW New Energy Vehicles and other enterprises, and strives to cultivate 15 companies with output value exceeding RMB 1 billion by next year. The total industrial output value of the automobile and parts supporting industries in the district exceeded RMB 50 billion.
Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.
Recently, the acquired F876L mutation of the AR identified in advanced prostate cancer cells was found to confer resistance to both enzalutamide and apalutamide. A newer antiandrogen, darolutamide (ODM-201), is not affected by this mutation, nor has it been found to be affected by any other tested/well-known AR mutations.; Apalutamide may be effective in a subset of prostate cancer patients with acquired resistance to abiraterone acetate.